Procalcitonin to Guide Antibiotic Stop in Neurocritical Care Patients.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03683693|
Recruitment Status : Recruiting
First Posted : September 25, 2018
Last Update Posted : September 25, 2018
Antibiotic overconsumption has been considered as one of the major contributive factors of the emergence of multidrug resistant bacteria, a serious threat particularly in intensive care units. Antibiotic stewardship programs are set up to meet this problem. Shortening the duration of antimicrobial therapy seems to be one of the strongest tools of these programs. Nevertheless, the decision to stop antibiotics in a critical care patients remains often challenging in real-life practice.
Procalcitonin (PCT), an inflammatory biomarker, has a promising profile and scores better than traditionally biomarkers as c-reactive protein (crp) and leucocytosis. Although two big multicenter randomised controlled trials showed a positive impact of PCT use in Intensive Care Unit (ICU), as it led to reduction of antibiotic exposure, the efficiency of this biomarker is still a point of debate. Notably the cost of PCT determination is a counterargument for its routinely use as it is a quite expensive test and its cost-benefit ratio has not been well studied.
The objective of this study is to test a PCT-algorithm for stopping antibiotics in a real life setting by assessing its impact on antibiotic consumption. The investigators hypothesize that it will shorten antimicrobial courses and will decrease overconsumption, with a possible positive impact on the increase of antimicrobial resistance and with no apparent adverse outcome.
|Condition or disease||Intervention/treatment||Phase|
|Sepsis||Diagnostic Test: Procalcitonin group||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||132 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Matched cohort: historical standard of care group (patients from the period January 2016 - April 2018) versus interventional group (patients from May 2018 on)|
|Masking:||None (Open Label)|
|Official Title:||Procalcitonin to Guide Antibiotic Stop in Neurocritical Care Patients. An Interventional Matched-cohort Study.|
|Actual Study Start Date :||May 7, 2018|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||September 2020|
No Intervention: Standard of Care group
Historical Group = Standard of Care group. Decision for stopping antibiotics taken by ICU physician: assessment on the basis of the clinical picture and traditional inflammatory biomarkers such as crp and leucocytosis
Experimental: Procalcitonin group
ICU physician gets on regular base PCT value, what can be used as additive tool in the decision-making for stopping antibiotics.
Diagnostic Test: Procalcitonin group
The ICU physician gets on regular base (day 0, d4, d7, d11, d15, d19, d23, d27) a PCT value and the according non-binding recommendation:
PCT < 0.5 microgram/L of 80% drop of the peak value : antibiotic stop recommended.
PCT < 0.25 microgram/L: antibiotic stop strongly recommended. The recommendation is not-binding and can be overruled by the ICU physician. The intervention is only set up for stopping antibiotics, not for initiating. PCT measurements only happens in case of still ongoing antibiotic course. In case of a second course of antibiotics, after interruption of the initial course, new PCT measurement will take place at this point followed by the continuation of the initial schedule of PCT measurement.
Intervention ends 28 days after inclusion.
- Antibiotic use [ Time Frame: at day 28 ]We will measure the duration of the first uninterrupted antibiotic course, expressed as Days of Therapy (DOT) and as Defined Defined Daily Doses (DDD) and the Antibiotic consumption during first 28 days expressed as antibiotic free days (alive) within the first 28 days after inclusion.
- ICU and mortality [ Time Frame: up to 6 months after inclusion ]We will measure ICU mortality from all causes and infection related ICU mortality by recording date of death
- 28-days mortality (from all causes) [ Time Frame: at day 28 ]We will measure 28-days mortality from all causes and infection related 28-days mortality by recording date of death
- Hospital mortality [ Time Frame: up to 6 months after inclusion ]date of death
- ICU and hospital length of stay [ Time Frame: up to 6 months after inclusion ]numbers of days in ICU and in hospital respectively
- Duration of Mechanical ventilation [ Time Frame: at day 28 ]numbers of days alive without ventilatory support (defined as unassisted breathing) during intervention period
- Recurrent infection [ Time Frame: at day 28 ]Number of patients with relapse or superinfection during ICU stay (patients requiring a new course of antibiotic therapy after a former fully completed course)
- Reinfection [ Time Frame: at day 28 ]Number of patients with microbiologically proven reinfection with the same pathogen in ICU
- Multidrug Resistance [ Time Frame: up to 3 months after inclusion ]Incidence of new multidrug resistant bacteria, isolated from specimens taken for routine microbiological assessment during ICU stay
- Multidrug Resistance [ Time Frame: up to 6 months after inclusion ]Incidence of new multidrug resistant bacteria, isolated from specimens taken for routine microbiological assessment during hospitalisation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03683693
|Contact: Stoffel Lamote, MDfirstname.lastname@example.org|
|Contact: Wouter De Corte, MD, PhDemail@example.com|
|Kortrijk, Belgium, 8500|
|Contact: Stoffel Lamote, MD|
|Principal Investigator:||Stoffel Lamote, MD||AZ Groeninge|